Skip to main content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

A critical analysis of test-retest reliability in instrument validation studies of cancer patients under palliative care: a systematic review

  • 1, 2, 3Email author,
  • 2,
  • 2, 3,
  • 1,
  • 1,
  • 3 and
  • 2, 3
BMC Medical Research Methodology201414:8

https://doi.org/10.1186/1471-2288-14-8

©  Paiva et al.; licensee BioMed Central Ltd. 2014

  • Received: 24 September 2013
  • Accepted: 13 January 2014
  • Published:
Open Peer Review reports

Abstract

Background

Patient-reported outcome validation needs to achieve validity and reliability standards. Among reliability analysis parameters, test-retest reliability is an important psychometric property. Retested patients must be in a clinically stable condition. This is particularly problematic in palliative care (PC) settings because advanced cancer patients are prone to a faster rate of clinical deterioration. The aim of this study was to evaluate the methods by which multi-symptom and health-related qualities of life (HRQoL) based on patient-reported outcomes (PROs) have been validated in oncological PC settings with regards to test-retest reliability.

Methods

A systematic search of PubMed (1966 to June 2013), EMBASE (1980 to June 2013), PsychInfo (1806 to June 2013), CINAHL (1980 to June 2013), and SCIELO (1998 to June 2013), and specific PRO databases was performed. Studies were included if they described a set of validation studies. Studies were included if they described a set of validation studies for an instrument developed to measure multi-symptom or multidimensional HRQoL in advanced cancer patients under PC. The COSMIN checklist was used to rate the methodological quality of the study designs.

Results

We identified 89 validation studies from 746 potentially relevant articles. From those 89 articles, 31 measured test-retest reliability and were included in this review. Upon critical analysis of the overall quality of the criteria used to determine the test-retest reliability, 6 (19.4%), 17 (54.8%), and 8 (25.8%) of these articles were rated as good, fair, or poor, respectively, and no article was classified as excellent. Multi-symptom instruments were retested over a shortened interval when compared to the HRQoL instruments (median values 24 hours and 168 hours, respectively; p = 0.001). Validation studies that included objective confirmation of clinical stability in their design yielded better results for the test-retest analysis with regard to both pain and global HRQoL scores (p < 0.05). The quality of the statistical analysis and its description were of great concern.

Conclusion

Test-retest reliability has been infrequently and poorly evaluated. The confirmation of clinical stability was an important factor in our analysis, and we suggest that special attention be focused on clinical stability when designing a PRO validation study that includes advanced cancer patients under PC.

Keywords

  • Validation studies
  • Test-retest reliability
  • Systematic review
  • Cancer
  • Palliative care

Background

Advanced cancer patients under palliative care (PC) experience many physical, psychosocial, and existential problems [1]. The PC team is essential for the screening, diagnosis, and treatment of cancer symptoms with the aim of improving the patients’ health-related quality of life (HRQoL). Therefore, an ideal assessment of symptoms and HRQoL should be performed using validated patient-reported outcome (PRO) instruments [2].

The process of PRO validation requires time and includes rigorous methods of data analysis. It encompasses the translation of foreign languages, cultural adaptation, and the evaluation of psychometric properties. Overall, a PRO validation needs to achieve the standards of validity and reliability [2]. Among reliability analyses, the most important are internal consistency, inter-rater reliability, and test-retest reliability. Test-retest reliability can be defined as “a measure of the reproducibility of the scale, that is, the ability to provide consistent scores over time in a stable population” [3].

Retested patients must be in a stable condition with respect to the construct to be measured by the PRO. This situation is particularly problematic in PC settings because advanced cancer patients are prone to a faster rate of clinical deterioration [4].

Thus, the aim of the present study was to evaluate the method by which multi-symptom and HRQoL PROs have been validated in oncological PC settings regarding test-retest reliability.

Methods

Design

A systematic literature review was used.

Eligibility criteria

The studies included in this systematic review met all of the following criteria: (1) validation study of a multidimensional quality of life instrument or a multidimensional symptom assessment instrument; (2) publication in a peer-reviewed journal; and (3) analysis of a population composed mainly of advanced cancer patients undergoing PC (or hospice care, end-of-life care, or some similar type of care).

Studies were excluded for any of the following reasons: (1) the study was not published as a full article (i.e., conference proceedings were excluded); (2) the study contained pediatric data; or (3) the publication was a duplicate publication.

Data sources

Validation studies of PROs were retrieved from the following online databases: PubMed (1966 to June 2013), EMBASE (1980 to June 2013), PsychInfo (1806 to June 2013), CINAHL (1980 to June 2013), and SCIELO (1998 to June 2013). The Patient-Reported Outcome and Quality of Life Instrument Database (PROQOLID) [5] (http://www.proqolid.org/) and the Australian Centre on Quality of Life (ACQOL) [6] (http://www.deakin.edu.au/research/acqol/index.php) were also used to search for validation studies.

Search strategy

Our search strategies for PubMed included the following: (1) quality of life instruments: (instrument OR questionnaire OR scale OR inventory OR checklist) AND (reliability OR test-retest OR validation OR psychometric* OR retest OR repeatability) AND (cancer OR tumor OR tumour OR carcinoma OR malignancy OR “neoplasms” [MESH]) AND “quality of life” AND (palliative care OR end-of-life OR “end of life” OR hospice OR terminal OR advanced); (2) multiple-symptom instruments: (instrument OR questionnaire OR scale OR inventory OR checklist) AND (reliability OR test-retest OR validation OR psychometric* OR retest OR repeatability) AND (cancer OR tumor OR tumour OR carcinoma OR malignancy OR “neoplasms” [MESH]) AND (symptom OR symptoms) AND (palliative care OR end-of-life OR “end of life” OR hospice OR terminal OR advanced). Searches using EMBASE, PsychInfo, CINAHL, and SCIELO were conducted by combining each of the terms used in the PubMed search strategy. With regards to the PROQOLID and ACQOL databases, references were individually screened. To identify additional papers, the reference lists of relevant articles were reviewed by one of the authors (CEP).

Data extraction

Initial searches (titles and abstracts) were conducted independently by CPS and FT. The studies with full text available were further reviewed, the data were independently extracted by two other reviewers (CEP, CPS), and the data were verified by a third reviewer (BSRP).

A standardized data collection form was used. The data collected included study demographics (year of publication, country in which the study was conducted, language in which the instrument was administered), the name of the instrument, and information about the characteristics of the patients enrolled (age, performance status). We also collected data regarding the statistical methods employed to perform the test-retest analysis, the time frame from test to retest, the total number of patients included in the study, and the number of patients included in the reliability test-retest analysis. If the sample size for the test-retest reliability was planned a priori, the study was included only if the article stated that the patient was clinically stable. The following QoL domains were systematically extracted from each article: global, physical, psychological, social, existential/spiritual, and functional. With regard to the symptoms, we specifically analyzed the pain, fatigue, nausea, anxiety, and depression domains.

Analytic approach

The COSMIN (COnsensus-based Standards for selection of health Measurement INstruments) checklist [7] was used to rate the methodological quality of the study designs. Because our focus was test-retest reliability, only the COSMIN Box B (reliability) was used. The “worst score counts” algorithm was used for the analysis [8]. Briefly, each item from COSMIN Box B was rated individually as “excellent”, “good”, “fair”, or “poor”, and an overall score was given by taking the lowest score of any of the items.

Because different statistical methods were used in many of the studies, a robust meta-analysis of the data was not possible. Therefore, to perform a pooled analysis, we followed the method of Terwee et al. [9] and accepted a minimum reliability threshold of 0.70 as a measure of “adequate test-retest results”. Each extracted domain was classified as the number of articles with test-retest values ≥ 0.70. The number of adequate test-retest results was associated with the evaluated outcome (HRQoL versus symptoms) and with the evidence provided for clinical stability, as measured by item 7 of COSMIN Box B. For this analysis, a chi-square test for linear trend was used. In addition, the time (in hours) to retest was compared between groups with adequate and non-adequate test-retest results using the Mann–Whitney U Test. Data are presented as median values and percentiles of 25 (P25) and 75 (P75).

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for building reviews were followed during the preparation of this review (see the PRISMA checklist in the Supplementary file).

Results

Figure 1 summarizes the identification and selection of studies. We identified 89 articles describing validation studies of PRO that evaluated advanced cancer patients under PC. Of those, 31 (34.8%) measured test-retest reliability. Information from the included studies is detailed in Table 1.
Figure 1
Figure 1

PRISMA flow diagram for search strategy.

Table 1

Instruments developed to assess symptoms or quality of life of cancer patients under palliative care

Author

Country (language)

Instrument

No. of items

Population profile

Sample

Time to retest

Objective confirmation of clinical stability

Type of statistics used

n (total)

n (retest)

Axelsson et al. [10]

Sweden (Swedish)

AQEL

22

ACP. Median age = 67.5 years, mean and median KPS = 62.3 and 70, respectively.

71

30

3 days

Not described

Spearman Rank correlation

Cohen et al. [11]

Canada (English)

MQOL

16

ACP. Could be receiving chemotherapy. Mean age: 59 years). Life expectancy greater than 2 weeks.

100

49-59

2 days

Yes

ICC

Llobera et al. [12]

Spain (Spanish)

HRCA-QL index

5

APC (end-of-life). Median survival = 59 days.

200

39

1 month (mean)

Yes

ICC

Mystakidou et al. [13]

Greece (Hellenic)

PLQI

28

Patients with symptomatic incurable cancer. Off anticancer treatment for ≥ 3 months. All patients classified as ECOG-PS ≥ 2 (ECOG-PS3 = 68%).

120

120

7 days

No

Spearman Rank correlation

Steinhauser et al. [14]

USA (English)

QUAL-E

25

Terminal CHF, ESRD, COPD, and stage IV cancer (56%).

248

135-170

7 days

Yes

ICC

Lopes Ferreira et al. [15]

Portugal (Portuguese)

POS

10

ACP (life expectancy < 1 year), non-terminal, many of them undergoing chemotherapy.

109

30

7 days

No

Pearson correlation

Suárez-del-Real et al. [16]

Mexico (Spanish)

QLQ-C15-PAL

15

ACP undergoing exclusive palliative care. KPS < =70% = 78%.

83

30

15.7 days (mean)

No

Repeated measures ANOVA

Leppert et al. [17]

Poland (Polish)

QLQ-C15-PAL

15

ACP undergoing palliative care.

129

129

7 days

No

Spearman Rank correlation

Kim et al. [18]

Korea (Korean)

MQLS

32

Mortality rate during study = 80%, ECOG-PS > = 3 = 71.2%.

70

54-64

3 hours and 7 days

No

ICC

Kim et al. [19]

Korea (Korean)

HQLS

43

Advanced cancer patients under exclusive palliative care. ECOG-PS3/4 = 64.2%.

180

88

1-2 weeks

No

Not described

Serra-Prat et al. [20]

Spain (Spanish)

POS

10

ACP under palliative care. Mean KPS = 50.93%.

200

Not described

1 week

Yes

ICC

Eisenchlas et al. [21]

Argentina (Spanish)

POS

10

ACP under palliative care. ECOG-PS 3/4 = 58%.

65

24

2 days

No

Weighted kappa agreement

Guo et al. [22]

USA (English)

Brief Hospice Inventory

17

Geriatric population (mean age = 78 years, 83% ≥ 70 years) 47% Advanced cancer under hospice care in 47%.

145

63

1 week

No

Not described

Lo et al. [23]

China (Chinese)

MQOL

16

Incurable ACP.

462

20

2 days

No

ICC

Shahidi et al. [24]

Iran (Persian)

MQOL

16

Mean KPS = 74.8%. Any type of incurable cancer with an estimated life expectancy of < 12 months was considered for the study.

61

Not clearly stated

24-72 hours

No

Pearson correlation

Harding et al. [25]

South Africa and Uganda (most spoke IsiZulu1)

APCA African Palliative Outcome Scale

10

Hospice patients, including ACP. Limited self-care and completely disabled = 41.7%.

682

307

21.2 hours (mean)

No

ICC

Hearn et al. [26]

England and Scotland (English)

POS

10

ACP (98%) under palliative care. Limited activity or disabled = 47.1%.

168

34

3-7 days

Yes

Weighted kappa agreement

Wilson et al. [27]

Canada (English)

SISC

13

ACP under palliative care. Median survival = 46 days.

68

46

1-3 days

No

Pearson correlation

Agra et al. [28]

Spain (Spanish)

RSCL

39

ACP under palliative care. Terminal illness (life expectancy < 6 months). KPS < 70% in 65.2%.

118

116

24 hours

No

ICC

Chang et al. [29]

USA (English)

ESAS

10

ACP under palliative care. Mostly elderly male patients.

233

19-23

1 day and 1 week

No

Spearman Rank correlation

Stiel et al. [30]

Germany (German)

MIDOS

12

ACP under palliative care. ECOG-PS 3/4 = 56.6%.

60

60

1 day

No

Pearson correlation

Moro et al. [31]

Italy (Italian)

ESAS

10

ACP under exclusive palliative care. In-patients, KPS ≤ 40 = 75%. Median survival = 35 days.

241

60

24-48 hours

No

ICC

Mystakidou et al. [32]

Greece (Greek)

MDASI

19

ACP under palliative care. ECOG-PS 3/4 = 63%.

150

100

3 days

No

Pearson correlation

Pautex et al. [33]

Swiss (French)

ESAS

10

ACP under palliative care. Mean age = 72 years.

42

42

1 day

No

Paired t test

Stiel et al. [34]

Germany (German)

HOPE-SP-CL

16

ACP under palliative care; inpatients.

31,055

332-472

7 days

No

Spearman Rank correlation

Carvajal et al. [35]

Spain (Spanish)

ESAS

10

ACP under palliative care. KPS ≤ 70% = 45.5%.

171

146

0-6 hours

No

Spearman Rank correlation and Lin’s Concordance test

Radbruch et al. [36]

Germany (German)

MIDOS

12

ACP under palliative care. ECOG-PS 3/4 = 81.2%.

128

76

1-6 days

Yes

Pearson correlation

Kwon et al. [37]

Korea (Korean)

ESAS

10

Mostly symptomatic ACP undergoing active antineoplastic treatment.

162

162

2-4 hours

No

Pearson correlation

Aoun et al. [38]

Australia (English)

SAS

7

ACP under palliative care.

572

60

2 hours

Yes

ICC

Pereira et al. [39]

Portugal (Portuguese)

FACT-G

28

ACP under PC (end-of-life). Inpatients and outpatients. Performance status not described.

346

27

8-9 days

No

Pearson correlation

Sterkenburg et al. [40]

Canada (English)

MQLS

32

Most were ACP under palliative care. Mean survival = 49.56 days.

84

73

3 hours and 7 days

No

ICC

USA United States of America, ICC intraclass correlation coefficient, CHF chronic heart failure, ANOVA Analysis of variance, ESRD end stage renal disease, COPD chronic obstructive pulmonary disease, AQEL Assessment of Quality of Life at the End of Life, MQOL McGill Quality of Life Questionnaire, HRCA-QL index Hebrew Rehabilitation Centre for Aged Quality of Life Index, PLQI The Palliative Care Quality of Life Instrument, QUAL-E Quality of Life at the End of Life, POS Palliative Care Outcome Scale, QLQ-C15-PAL The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL, MQLS McMaster Quality of Life Scale, HQLS Hospice Quality of Life Scale, SISC Structured Interview for Symptoms and Concerns, RSCL Rotterdam Symptom Check List, ESAS Edmonton Symptom Assessment System, MIDOS Minimal Documentation System, MDASI MD Anderson Symptom Inventory, HOPE-SP-CL Multidimensional symptom and problem checklist, SAS Symptom Assessment Scale, FACT-G Functional Assessment of Cancer Therapy- General. 1 IsiZulu (49.6%), English (15.3%), isiXhosa (12.8%), Luganda (6.4%), SeSotho (6.3%), Runyoro (5.4%), Runyankole (3.9%), and SeTswana (0.4%).2 7 for the patients and 3 for the caregivers.

Methodological quality of the studies

Two authors (CEP, EMB) classified the articles according to the COSMIN guidelines; the percentage of agreement between coders was 85.3% (Cohen’s Kappa coefficient = 0.764). Any disagreements in interpretation were resolved by a discussion with a third author (BSRP). There were 4 (12.9%) [11, 25, 28, 40], 17 (54.8%) [10, 12–15, 18, 20, 24, 26, 27, 30–32],[34, 36–38], and 10 (32.2%) [16, 17, 19, 21–23, 29, 33, 35, 39] articles classified as good, fair, and poor, respectively, with regards to the overall quality criteria. No article was classified as excellent according to the aforementioned criteria. The global quality classification per item is described in Figure 2.
Figure 2
Figure 2

Quality criteria of the included studies according to the COSMIN checklist.

Sample sizes

A total of 29 studies (29 of 31; 93.5%) [10–19, 21–23, 25–40] described the number of patients submitted to the test-retest analysis. Of those, the median (P25-P75) number of patients included was 60 (32–119). The majority of the studies (24 of 29; 82.8%) [10–12, 14–16, 18, 19, 21–23, 25–29, 31, 32],[34–36, 38–40] included fewer than the total number of patients for the reliability analysis. Overall, 53.8% (95% CI 19.6%-87.9%) of the total number of analyzed patients were used for the test-retest reliability analysis. Only 2 articles [28, 37] described the sample size calculation for the test-retest analysis. One study [35] used a reference from others recommending that at least 50 patients should be used for this type of statistical analysis.

Time to retest

The time interval to retest was clearly stated in all of the included studies [10–40]. The median (P25-P75) time was 72 (27–168) hours. The median (P25-P75) time intervals for the retest were 24 (3.25-60) hours and 168 (48–204) hours for the symptom and HRQoL validation studies, respectively (p = 0.001).

Confirmation of clinical stability

Of the 31 analyzed articles, 10 (10 of 31, 32.3%) [11–15, 20, 21, 26, 36, 38] clearly stated that only clinically stable patients were submitted to the retest. The confirmation of clinical stability in accordance with the COSMIN checklist was associated with adequate results for the test-retest analysis regarding both pain and global HRQoL scores (p < 0.05, Table 2). Of those studies, 6 used 1 or more of the following objective criteria to define a stable condition: patient perception of change (n = 2) [11, 20]; stable doses of opiates (n = 1) [36] or lack of a new medication for symptom treatment (n = 2) [14, 38]; emergency department visit and/or hospitalization (n = 1) [14]; and change in Performance Status or in daily living activities (n = 1) [12].
Table 2

Association between the test-retest reliability values and the evidence of clinical stability

Test-retest values

Were patients stable in the interim period on the construct to be measured?

P*

Poor

Fair

Good

Excellent

N (%)

N (%)

N (%)

N (%)

Global HRQoL scores

    

0.015

   < 0.70

2 (18.2)

5 (45.5)

4 (36.4)

0 (0)

 

   ≥ 0.70

0 (0)

1 (12.5)

5 (62.5)

2 (25.0)

 

Pain scores

    

0.031

   < 0.70

2 (18.2)

3 (27.3)

3 (27.3)

1 (9.1)

 

   ≥ 0.70

0 (0)

1 (11.1)

4 (44.4)

4 (44.4)

 

HRQoL health-related quality of life.

*p-value for linear trend.

Scores of retest

In the present review, we chose to perform statistical comparisons only for the pain and global HRQoL scores because they were the most commonly described domains in the selected studies (Table 3). Taking into consideration a set value of ≥ 0.70 as an adequate result in the test-retest analysis, 50% (9 of 18, 50%) [13, 20, 25, 29, 32, 35–38] and 45% (9 of 20, 45%) [10–12, 18, 23–25, 32, 40] of the studies with pain and global HRQoL values, respectively, were considered adequate.
Table 3

Number of studies with adequate and non-adequate test-retest values

Evaluated domains

Number of studies

Test-retest values

<0.70

≥0.70

n (%)

n (%)

Global HRQoL

19

11 (57.9)

8 (42.1)

Emotional

8

1 (12.5)

7 (87.5)

Physical

5

1 (20)

4 (80)

Social

6

2 (33.3)

4 (66.7)

Functioning

3

0 (0)

3 (100)

Existential

6

1 (16.7)

5 (83.3)

Global symptoms

5

2 (40)

3 (60)

Pain

18

9 (50)

9 (50)

Nausea

12

5 (41.6)

7 (58.3)

Fatigue

11

6 (54.5)

5 (45.5)

Anxiety

10

6 (60)

4 (40)

Depression

9

4 (44.4)

5 (55.6)

HRQoL health-related quality of life.

There was a non-significant trend favoring shorter time intervals for the retest in the studies with adequate results for the retest statistical analysis (value ≥ 0.70) in comparison with those with non-satisfactory results (value <0.70) (Table 4).
Table 4

Median values of time intervals of studies with non-adequate (<0.70) and adequate (≥0.70) test-retest values

Evaluated domains

Number of studies

Time interval (hours) Median (Q1-Q3)

p-value*

Test-retest < 0.70

Test-retest ≥ 0.70

Global HRQoL

19

168 (36–168)

60 (36.75-206)

0.565

Emotional

8

1681

168 (48–204)

-

Physical

5

1681

108 (30–195)

-

Social

6

1862

108 (48–195)

-

Functioning

3

-

1683

-

Existential

6

1201

168 (48–232)

-

Global symptoms

5

25.752

483

-

Pain

18

120 (42–168)

48 (3–168)

0.262

Nausea

12

108 (33–168)

24 (3–72)

0.146

Fatigue

11

48 (24–168)

3 (2.5-120)

0.184

Anxiety

10

72 (36–168)

48 (8.25-144)

0.443

Depression

9

102 (27–168)

60 (18.75-96)

0.587

HRQoL health-related quality of life.

*Mann–Whitney test.

1Only one study. 2Only two studies. 3Only three studies.

Three studies [18, 29, 40] compared 2 different time frame intervals for the retest. Two of them [18, 40] measured global HRQoL 3 hours and 7 days after the first evaluation; the test-retest results were 0.84-0.93 and 0.63 at 3 hours and 7 days, respectively. The other validation study [29] evaluated cancer symptoms using the Edmonton Symptom Assessment System (ESAS) scale. That study found higher test-retest values for shorter time intervals, with the exception of the symptom of fatigue (Table 5).
Table 5

Test-retest reliability scores measured at two different time intervals from the first evaluation

Author (year)

Time to retest

Scores

Global HRQoL

Pain

Nausea

Fatigue

Anxiety

Depression

Kim et al. [18]

3 hours

0.93

NA

NA

NA

NA

NA

7 days

0.63

NA

NA

NA

NA

NA

Chang et al. [29]

24 hours

NA

0.79

0.58

0.39

0.62

0.81

7 days

NA

0.75

0.31

0.65

0.35

0.54

Sterkenburg et al. [40]

3 hours

0.84

NA

NA

NA

NA

NA

7 days

0.63

NA

NA

NA

NA

NA

NA not evaluated.

Statistical methods used

Of those instruments with continuous scores (n = 29), 11 (11 of 29, 37.9%) [11, 12, 14, 18, 20, 23, 25, 28],[31, 38, 40] evaluated the test-retest reliability using the intraclass correlation coefficient, and 14 (14 of 29, 48.3%) [10, 13, 15, 17, 24, 27, 29, 30],[32, 34–37, 39] performed some type of correlation analysis such as Spearman’s (n = 6) or Pearson’s (n = 8) test. Interestingly, for those studies in which the intraclass correlation coefficient (ICC) method was used, none described the statistical model or formula used; therefore, no study could be classified as “excellent” according to item 11 in Box B of the COSMIN guidelines. Two studies used paired analysis (repeated measures of analysis of variance [ANOVA], n = 1; paired t test, n = 1) to evaluate test-retest reliability [16, 33]. Three studies with ordinal score instruments calculated the weighted kappa statistic [20, 21, 26]. Two studies did not describe the type of statistics used [19, 22].

Discussion

In this study, we investigated the methods by which validation studies of PRO have been performed in the PC setting, particularly with regards to test-retest reliability. In general, the methodological quality of this psychometric property was investigated poorly to fairly; according to the COSMIN checklist, only 12.3% of the studies were considered of good quality, and none were considered of excellent quality. In addition, we highlighted the importance of verifying the clinical stability of advanced cancer patients before performing the retest. Based on our results, clinical stability is even more important for test-retest reliability than the accurate definition of the time interval at which the retest is performed.

In our review, we identified 89 validation studies that included cancer symptoms and/or HRQoL as outcome variables. Of those, only 31 (34.8%) evaluated the test-retest reliability. As the test-retest reliability is an essential psychometric property to be measured in validation studies, we hypothesize that researchers are not systematically measuring it because of the instability of advanced cancer patients. Overall, half of the evaluated test-retest reliability scores were classified as inadequate when 0.70 was used as the threshold value [9]. The pressure experienced by scientific researchers to publish positive results [41] may also explain why only 34.8% of validation studies measured the test-retest reliability. Furthermore, it is possible that inappropriate test-retest values were omitted from some publications.

It is essential to accurately estimate the sample size prior to beginning a study. An insufficient sample size might not detect true differences, which might lead to unreliable results. Conversely, an excessive sample size may produce unnecessary financial losses and ethical concerns regarding futile exposure of study participants [42]. With regards to test-retest reliability analysis, we observed that determining an adequate sample size is not a common practice because only 2 studies [28, 37] described performing a sample size calculation prior to the study. Overall, the median number of included patients for test-retest analysis was 60, which represents 53.8% of the total number of included patients. One study [35] justified the sample size by citing a rule of thumb suggesting that 50 patients would be sufficient for the analysis [43, 44].

A basic concept regarding test-retest reliability is the need to retest clinically stable patients [45]. The retest of advanced cancer patients is challenging because they are in a dynamic phase of their disease in which symptoms and functionality are prone to decline quickly. The retest of a clinically unstable patient may incorrectly define a PRO as a non-reliable tool. Our results confirm the importance of verifying the clinical stability of the patients before retesting. In addition, our review described the objective criteria used by some studies to define a stable condition.

The definition of an adequate between-assessment time gap for the retest is of the utmost importance. An insufficient time period might allow respondents to recall their first answers, and a longer interval might allow for a true change of the construct to occur [2, 45]. The appropriate time interval depends on the construct to be measured and the target population [46]; however, approximately 2 weeks is often considered generally appropriate [47]. Nevertheless, the time interval over which to retest advanced cancer patients under PC is still a matter of debate. Some authors have considered retesting advanced cancer patients at least 3 days apart as a measure of responsiveness but not as a measure of test-retest reliability [4].

In fact, because of concerns about reassessing an unstable patient, some authors (n = 7) reapplied the questionnaires at very short intervals (i.e., less than 24 hours). Jim et al. [48] investigated daily and intraday changes in the fatigue, depression, sleep, and activity scores in a cohort of cancer patients undergoing chemotherapy. Significant changes were observed over time. Additionally, Dimsdale et al. [49] investigated cancer-related fatigue every hour for 72 consecutive hours and observed a diurnal variation in fatigue. HRQoL, on the other hand, is a multidimensional construct that encompass physical, psychological, social, and spiritual domains. In general, instruments that measure HRQoL use recall periods of 7 days. Although HRQoL is not commonly assessed on a daily basis, it is expected to behave stably over a few days, especially the social, existential, and global domains. Consequently, we observed that multi-symptom instruments are generally retested within a shorter time frame than HRQoL instruments.

There was a trend of shorter time periods in the adequate test-retest reliability results when compared with the scores with inadequate results (less than 0.7). One reason contributing to the non-significant results might be the large interquartile range for some of the domains; since few studies were analyzed, there was insufficient statistical power for further conclusions. Three studies [18, 29, 40] evaluated the retest reliability at 2 different time points (< 24 hours and 1 week after the first evaluation); in general, a lower time interval was associated with a better retest analysis result. Considering the median time interval used in the studies with adequate test-retest results, in addition to the findings from studies that used two different time intervals for the retest, we can recommend that patients under palliative care for advanced cancer should be retested somewhere around 24 to 48 hours later when evaluating cancer symptoms and 2 to 7 days later when assessing HRQoL. However, we believe that the most important factor is not the time itself but rather confirmation of clinical stability before retesting patients.

As mentioned previously, we concluded that the test-retest reliability analysis was of low quality according to the COSMIN checklist. Other studies using the same guidelines but not the same population have yielded similar results [50–52]. The most troublesome question in our review was item 11 (“for continuous scores: was an intraclass correlation coefficient calculated?”), with 62% of studies classified as poor to fair quality. The preferred test-retest reliability statistic depends on the type of response options. In our review, the majority of the studies evaluated continuous scores. In these cases, the ICC [31] is the preferred statistic [46, 47, 53]. Moreover, the use of correlation coefficients (Pearson’s and Spearman’s tests) is not adequate because they do not include a consideration of systematic error [46]. In the present study, 18 of 29 studies evaluating continuous scores used a correlation analysis, but they did not evaluate the agreement by using the ICC. Six different versions of ICC can be used depending on various assumptions, and 4 of those are subdivided into consistency or absolute agreement, yielding a total of 10 different ICC calculations [54]. The choice of the correct index has a highly significant impact on the numerical value of the ICC [53]. Even in those studies that correctly used the ICC, none stated the version of the ICC used.

This study has some limitations. Because the studies evaluated test-retest reliability using different statistics, we could not perform a robust meta-analysis. Therefore, we decided to use 0.7 as the threshold for adequate results on test-retest reliability to perform a pooled data analysis. However, the categorization of the test-retest results as a function of a predefined cut-off point may be considered an inadequate simplification. Another limitation is that we did not include in the systematic review other instruments developed to assess only one symptom (fatigue or pain scales, for example). In addition, we did not include abstracts from meetings because it would be difficult to extract the necessary data.

Conclusions

In conclusion, we determined that test-retest reliability has been infrequently and poorly evaluated in validation studies of PRO assessing advanced cancer patients under PC. Multi-symptom instruments were retested over a shorter time interval when compared to HRQoL. The confirmation of clinical stability was an important factor in our analysis, and we suggest that special attention to this parameter is required when designing a PRO validation study that includes advanced cancer patients under PC.

Declarations

Authors’ Affiliations

(1)
Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, CEP 14784-400, Brazil
(2)
Palliative Care and Quality of Life Research Group, Post-Graduate Program, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
(3)
Researcher Support Center, Learning and Research Institute, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

References

  1. Ferrell B, Paice J, Koczywas M: New standards and implications for improving the quality of supportive oncology practice. J Clin Oncol. 2008, 26 (23): 3824-3831. 10.1200/JCO.2007.15.7552.View ArticlePubMedGoogle Scholar
  2. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD, Mayo FDAP-ROCMG: What is sufficient evidence for the reliability and validity of patient-reported outcome measures?. Value Health. 2007, 10 (Suppl 2): S94-S105.View ArticlePubMedGoogle Scholar
  3. Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, Stein RE: Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002, 11 (3): 193-205. 10.1023/A:1015291021312.View ArticlePubMedGoogle Scholar
  4. Richardson LA, Jones GW: A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol. 2009, 16 (1): 55-PubMedPubMed CentralGoogle Scholar
  5. The Patient-Reported Outcome and Quality of Life Instrument Database (PROQOLID). http://www.proqolid.org/,
  6. Australian Centre on Quality of Life (ACQOL). http://www.deakin.edu.au/research/acqol/index.php,
  7. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HC: The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010, 19 (4): 539-549. 10.1007/s11136-010-9606-8.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC: Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012, 21 (4): 651-657. 10.1007/s11136-011-9960-1.View ArticlePubMedGoogle Scholar
  9. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC: Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007, 60 (1): 34-42. 10.1016/j.jclinepi.2006.03.012.View ArticlePubMedGoogle Scholar
  10. Axelsson B, Sjoden PO: Assessment of quality of life in palliative care–psychometric properties of a short questionnaire. Acta Oncol. 1999, 38 (2): 229-237. 10.1080/028418699431663.View ArticlePubMedGoogle Scholar
  11. Cohen SR, Mount BM: Living with cancer: “good” days and “bad” days–what produces them? Can the McGill quality of life questionnaire distinguish between them?. Cancer. 2000, 89 (8): 1854-1865. 10.1002/1097-0142(20001015)89:8<1854::AID-CNCR28>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
  12. Llobera J, Esteva M, Benito E, Terrasa J, Rifa J, Pons O, Maya A: Quality of life for oncology patients during the terminal period. Validation of the HRCA-QL index. Support Care Cancer. 2003, 11 (5): 294-303.PubMedGoogle Scholar
  13. Mystakidou K, Tsilika E, Kouloulias V, Parpa E, Katsouda E, Kouvaris J, Vlahos L: The “Palliative Care Quality of Life Instrument (PQLI)” in terminal cancer patients. Health Qual Life Outcomes. 2004, 2: 8-10.1186/1477-7525-2-8.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Steinhauser KE, Clipp EC, Bosworth HB, McNeilly M, Christakis NA, Voils CI, Tulsky JA: Measuring quality of life at the end of life: validation of the QUAL-E. Palliat Support Care. 2004, 2 (1): 3-14.View ArticlePubMedGoogle Scholar
  15. Lopes Ferreira P, Pinto Barros A: Measuring quality of life in palliative care. Acta Med Port. 2008, 21 (2): 111-124.PubMedGoogle Scholar
  16. Suarez-del-Real Y, Allende-Perez S, Alferez-Mancera A, Rodriguez RB, Jimenez-Toxtle S, Mohar A, Onate-Ocana LF: Validation of the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care. Psychooncology. 2011, 20 (8): 889-896. 10.1002/pon.1801.View ArticlePubMedGoogle Scholar
  17. Leppert W, Majkowicz M: Validation of the Polish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care in patients with advanced cancer. Palliat Med. 2013, 27 (5): 470-477. 10.1177/0269216312458823.View ArticlePubMedGoogle Scholar
  18. Kim KU, Yoon SJ, Lee JL, Ahn HS, Park HJ, Lee SI, Jo MW: Validation of the Korean version of the McMaster Quality of Life Scale in terminal cancer patients. J Palliat Care. 2006, 22 (1): 40-45.PubMedGoogle Scholar
  19. Kim SH, Choi YS, Lee J, Oh SC, Yeom CH, Lee MA, Kim DG, Moon Do H, Kim DY, Koh SJ: Reliability and validity of the Hospice Quality of Life Scale for Korean cancer patients. J Pain Symptom Manage. 2009, 37 (2): 156-167. 10.1016/j.jpainsymman.2008.02.008.View ArticlePubMedGoogle Scholar
  20. Serra-Prat M, Nabal M, Santacruz V, Picaza JM, Trelis J, Grupo Catalan de Estudio de la Efectividad de los Cuidados P: Validation of the Spanish version of the palliative care outcome scale. Med Clin. 2004, 123 (11): 406-412.View ArticleGoogle Scholar
  21. Eisenchlas JH, Harding R, Daud ML, Perez M, De Simone GG, Higginson IJ: Use of the palliative outcome scale in Argentina: a cross-cultural adaptation and validation study. J Pain Symptom Manage. 2008, 35 (2): 188-202. 10.1016/j.jpainsymman.2007.02.045.View ArticlePubMedGoogle Scholar
  22. Guo H, Fine PG, Mendoza TR, Cleeland CS: A preliminary study of the utility of the brief hospice inventory. J Pain Symptom Manage. 2001, 22 (2): 637-648. 10.1016/S0885-3924(01)00296-2.View ArticlePubMedGoogle Scholar
  23. Lo RS, Woo J, Zhoc KC, Li CY, Yeo W, Johnson P, Mak Y, Lee J: Cross-cultural validation of the McGill Quality of Life questionnaire in Hong Kong Chinese. Palliat Med. 2001, 15 (5): 387-397. 10.1191/026921601680419438.View ArticlePubMedGoogle Scholar
  24. Shahidi J, Khodabakhshi R, Gohari MR, Yahyazadeh H, Shahidi N: McGill Quality of Life Questionnaire: reliability and validity of the Persian version in Iranian patients with advanced cancer. J Palliat Med. 2008, 11 (4): 621-626. 10.1089/jpm.2007.0173.View ArticlePubMedGoogle Scholar
  25. Harding R, Selman L, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, et al: Validation of a core outcome measure for palliative care in Africa: the APCA African Palliative Outcome Scale. Health Qual Life Outcomes. 2010, 8: 10-10.1186/1477-7525-8-10.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Hearn J, Higginson IJ: Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Care. 1999, 8 (4): 219-227. 10.1136/qshc.8.4.219.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Wilson KG, Graham ID, Viola RA, Chater S, de Faye BJ, Weaver LA, Lachance JA: Structured interview assessment of symptoms and concerns in palliative care. Can J Psychiatry. 2004, 49 (6): 350-358.PubMedGoogle Scholar
  28. Agra Y, Badia X: Spanish version of the Rotterdam Symptom Check List: cross-cultural adaptation and preliminary validity in a sample of terminal cancer patients. Psychooncology. 1998, 7 (3): 229-239. 10.1002/(SICI)1099-1611(199805/06)7:3<229::AID-PON302>3.0.CO;2-R.View ArticlePubMedGoogle Scholar
  29. Chang VT, Hwang SS, Feuerman M: Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000, 88 (9): 2164-2171. 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
  30. Stiel S, Matthes ME, Bertram L, Ostgathe C, Elsner F, Radbruch L: Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS). Schmerz. 2010, 24 (6): 596-604. 10.1007/s00482-010-0972-5.View ArticlePubMedGoogle Scholar
  31. Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M, Labianca R, Ripamonti C: Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer. 2006, 14 (1): 30-37. 10.1007/s00520-005-0834-3.View ArticlePubMedGoogle Scholar
  32. Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E, Vlahos L, Mendoza T: Greek M.D. Anderson symptom inventory: validation and utility in cancer patients. Oncology. 2004, 67 (3–4): 203-210.View ArticlePubMedGoogle Scholar
  33. Pautex S, Berger A, Chatelain C, Herrmann F, Zulian GB: Symptom assessment in elderly cancer patients receiving palliative care. Crit Rev Oncol Hematol. 2003, 47 (3): 281-286. 10.1016/S1040-8428(03)00043-X.View ArticlePubMedGoogle Scholar
  34. Stiel S, Pollok A, Elsner F, Lindena G, Ostgathe C, Nauck F, Radbruch L: Validation of the symptom and problem checklist of the German Hospice and Palliative Care Evaluation (HOPE). J Pain Symptom Manage. 2012, 43 (3): 593-605. 10.1016/j.jpainsymman.2011.04.021.View ArticlePubMedGoogle Scholar
  35. Carvajal A, Centeno C, Watson R, Bruera E: A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer. 2011, 47 (12): 1863-1872. 10.1016/j.ejca.2011.03.027.View ArticlePubMedGoogle Scholar
  36. Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Elsner F, Hormann E: MIDOS–validation of a minimal documentation system for palliative medicine. Schmerz. 2000, 14 (4): 231-239. 10.1007/s004820070028.View ArticlePubMedGoogle Scholar
  37. Kwon JH, Nam SH, Koh S, Hong YS, Lee KH, Shin SW, Hui D, Park KW, Yoon SY, Won JY, et al: Validation of edmonton symptom assessment system in korean patients with cancer. J Pain Symptom Manage. 2013, 46 (6): 947-956. 10.1016/j.jpainsymman.2013.01.012.View ArticlePubMedGoogle Scholar
  38. Aoun SM, Monterosso L, Kristjanson LJ, McConigley R: Measuring symptom distress in palliative care: psychometric properties of the Symptom Assessment Scale (SAS). J Palliat Med. 2011, 14 (3): 315-321. 10.1089/jpm.2010.0412.View ArticlePubMedGoogle Scholar
  39. Pereira F, Santos C: Estudo de adaptação cultural e validação da Functional Assessment of Cancer Therapy-General em cuidados paliativos. Rev Enferm Referênci. 2011, 5: 10-Google Scholar
  40. Sterkenburg CA, King B, Woodward CA: A reliability and validity study of the McMaster Quality of Life Scale (MQLS) for a palliative population. J Palliat Care. 1996, 12 (1): 18-25.PubMedGoogle Scholar
  41. Fanelli D: Do pressures to publish increase scientists’ bias? An empirical support from US States Data. PLoS One. 2010, 5 (4): e10271-10.1371/journal.pone.0010271.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Guo Y, Logan HL, Glueck DH, Muller KE: Selecting a sample size for studies with repeated measures. BMC Med Res Methodol. 2013, 13: 100-10.1186/1471-2288-13-100.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Hopkins WG: Measures of reliability in sports medicine and science. Sports Med. 2000, 30 (1): 1-15. 10.2165/00007256-200030010-00001.View ArticlePubMedGoogle Scholar
  44. Atkinson G, Nevill A: Typical error versus limits of agreement. Sports Med. 2000, 30 (5): 375-381.View ArticlePubMedGoogle Scholar
  45. Fayers P, Machin D: Quality of Life. Assessment, Analysis and Interpretation. 2007, Chichester: John Wiley, 2Google Scholar
  46. The COSMIN checklist manual. http://www.cosmin.nl,
  47. Streiner DL, Norman GR: Health Measurement Scales. A Practical Guide to Their Development and use. 2008, New York: Oxford University Press, 4View ArticleGoogle Scholar
  48. Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen PB: Fatigue, depression, sleep, and activity during chemotherapy: daily and intraday variation and relationships among symptom changes. Ann Behav Med. 2011, 42 (3): 321-333. 10.1007/s12160-011-9294-9.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Dimsdale JE, Ancoli-Israel S, Ayalon L, Elsmore TF, Gruen W: Taking fatigue seriously, II: variability in fatigue levels in cancer patients. Psychosomatics. 2007, 48 (3): 247-252. 10.1176/appi.psy.48.3.247.View ArticlePubMedGoogle Scholar
  50. Vrijman C, Homan ML, Limpens J, van der Veen W, Wolkerstorfer A, Terwee CB, Spuls PI: Measurement properties of outcome measures for Vitiligo: a systematic review. Arch Dermatol. 2012, 148 (11): 1302-1309. 10.1001/archdermatol.2012.3065.View ArticlePubMedGoogle Scholar
  51. Abma FI, van der Klink JJ, Terwee CB, Amick BC, Bultmann U: Evaluation of the measurement properties of self-reported health-related work-functioning instruments among workers with common mental disorders. Scand J Work Environ Health. 2012, 38 (1): 5-18. 10.5271/sjweh.3190.View ArticlePubMedGoogle Scholar
  52. Reimers AK, Mess F, Bucksch J, Jekauc D, Woll A: Systematic review on measurement properties of questionnaires assessing the neighbourhood environment in the context of youth physical activity behaviour. BMC Public Health. 2013, 13: 461-10.1186/1471-2458-13-461.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Werner MU, Petersen MA, Bischoff JM: Test-retest studies in quantitative sensory testing: a critical review. Acta Anaestheriol Scand. 2013, 57 (8): 957-963. 10.1111/aas.12150.View ArticleGoogle Scholar
  54. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979, 86 (2): 420-428.View ArticlePubMedGoogle Scholar

    55. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2288/14/8/prepub

Copyright

© Paiva et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us